TEDOFA Trial Study Protocol: A Prospective Double-Blind, Randomized, Controlled Clinical Trial Comparing Opioid-Free versus Opioid Anesthesia on the Quality of Postoperative Recovery and Chronic Pain in Patients Receiving Thoracoscopic Surgery
Bijia Song,Xiuliang Li,Jiguang Yang,Wenjing Li,Lei Wan
DOI: https://doi.org/10.2147/jpr.s438733
IF: 2.8319
2024-02-13
Journal of Pain Research
Abstract:Bijia Song, Xiuliang Li, Jiguang Yang, Wenjing Li, Lei Wan Department of Anesthesiology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People's Republic of China Correspondence: Lei Wan, Email Introduction: Seeking effective multimodal analgesia and anesthetic regimen is the basis for the success of ERAS. Opioid-free anesthesia (OFA) is a multimodal anesthesia associating hypnotics, N-methyl-D-aspartate (NMDA) antagonists, local anesthetics, anti-inflammatory drugs and α-2 agonists. Although previous studies have confirmed that OFA is safe and feasible for VATS surgery, there is great heterogeneity in how to select and combine anti-harm drugs to replace opioids. We hypothesized that the reduced opioid use during and after surgery allowed by OFA compared with standard of care will be associated with a reduction of postoperative opioid-related adverse events and an improvement in the quality of rehabilitation of patients after partial VATS lung resection. Methods/Analysis: The TEDOFA Study is a prospective double-blind, randomized, controlled clinical trial with a concealed allocation of patients scheduled to undergo elective partial VATS pneumonectomy 1:1 to receive either a standard anesthesia protocol or an OFA. A total of 146 patients were recruited in the study. Primary endpoint was the 15-item recovery quality scale (QoR-15) at 24 hours after surgery. Ethics and Dissemination: This trial has been approved by the Institutional Review Board of Beijing Friendship Hospital of China Capital University. The TEDOFA trial study protocol was approved on 27 February 2023. The trial started recruiting patients after registered on the Chinese Clinical Trial Registry. Trial Registration Number: ChiCTR2300069210; Pre-results. Keywords: opioid-free anesthesia, thoracoscopic surgery, postoperative recovery, chronic pain Lung cancer is the leading cause of cancer-related mortality for both men and women all over the world. 1 Annually, approximately 631000 deaths were reported because of lung cancer according to Chinese national statistics. 2 In contrast to the decline in lung cancer incidence in Western countries, it is still rising in China, which is a major public health problem and places a huge burden on society. Despite tremendous advances in targeted therapies, immunotherapy, and radiotherapy, complete surgical resection still remains the gold standard for curative treatment of early-stage non-small-cell lung cancer in patients who are physiologically fit. Traditionally, resection is done via a thoracotomy, but during the past two decades, video-assisted thoracoscopic surgery (VATS) has emerged as a minimally invasive alternative for advanced resections, including lobectomy. According to many authors, VATS lobectomy decreases postoperative pain, induces less impairment in pulmonary function, and has a shorter chest tube duration and, consequently, a shorter hospital stay. 3,4 Results from many non-randomized studies have suggested that VATS is less traumatic than thoracotomy, resulting in less postoperative pain, less perioperative bleeding, shorter hospital stays, and earlier return to normal activities. 3,4 However, due to intercostal nerve compression, muscle and fascia injury, soft tissue edema around the incision, and thoracic drainage tube placement, the proportion of patients with acute pain at 24 hours after VATS [numerical rating scale, (NRS) ≥3] was 38%, 5 up to 3.4% of patients with severe pain (NRS ≥7). 6 Improper postoperative acute pain management not only increases the incidence of postoperative pulmonary complications such as postoperative pneumonia, atelectasis or respiratory failure, affecting rapid recovery and prolonged hospital stay, but also are risk factors for postoperative analgesic use and development of chronic postoperative pain (CPSP), depression, and delirium. 7,8 Since the 1960s, intraoperative administration of opioids is considered a keystone of anesthesia as well as hypnotics and muscle relaxants. For most common surgeries, opioids are irreplaceable drugs for analgesia regimens. Thoracic surgery is a much more challenging field associated with a higher rate of pain and pulmonary complications compared to other surgeries. Adequate analgesia after thoracic surgery is essential for a successful outcome. 9 However, opioid administration consequences are neither scarce nor benign for the patient. Perioperative opioids are associated with nausea and vomiting, 10 sedation, 11 ileus, 12 confusion/delirium, 13 respiratory depression, 14 increased postoperative pain and morphine consumption, 15 immunodepression, 16 hyperalgesia a -Abstract Truncated-
clinical neurology